Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
about
Maraviroc: the evidence for its potential in the management of HIVTrends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North AmericaMissing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.Assessing the performance of a computer-based policy model of HIV and AIDSInfluence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failureTriple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 yearsTriple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections.Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patientsTipranavir: a protease inhibitor for multi-drug resistant HIV-1.Predictors of antiretroviral treatment failure in an urban HIV clinic.Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.Maraviroc: a new CCR5 antagonist.Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.Elucidation of the time course of adenosine deaminase APOBEC3G and viral infectivity factor vif in HIV-2(287) -infected infant macaques.Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico.The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in PortugalUS cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trials.Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized, controlled trial.Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients.
P2860
Q28476655-6B640BEE-517C-4A8F-9C0D-7DF226BAC7F9Q33853922-8A293B0B-E5DB-4332-8474-725532376C64Q33981074-98054D3C-CA47-4BC1-A5E1-ABED2C236E06Q34115343-6D282139-F04E-4CFA-BE77-2BB4313DF0EFQ35070832-53008E66-EF43-42AB-814C-0C58F8810F29Q35698801-C1F85F64-87F4-444B-B00A-C43E912C25B9Q35870814-278D9745-B65F-496C-A490-3C7792D55A5DQ35903886-5C4D297A-9AB4-4E37-B282-440534660FE1Q36091962-6ADDB6E6-4D80-4739-8B53-AEE4410863EBQ36349653-59908944-9CF8-43C2-BA9E-32E8E3A3177EQ36628011-6A45D0C3-67A3-49C9-B06B-A0A6354FD465Q37379360-66FFED76-48C6-4E84-8B9D-DE4F22104144Q37463958-7E3A3F77-9A46-48CB-BBA7-F515DE3815A9Q37557671-F83DA3DC-BBA8-40BC-918A-B7FC817B97ECQ37653463-5C1CE0A9-522C-4C2A-B001-01F20A547D1EQ37823558-A4217FC3-41AC-40B0-9AB8-6723E56F9EC8Q38428663-3FDC8AE2-7C0C-44F0-95C4-EF643018F7B3Q39454853-C9079566-317E-43A9-B487-605C181161CFQ41567745-C15246A2-0912-4956-B9BA-E2F2DCB4474CQ42742963-B3B9C575-EB52-4EBD-A158-250D13D672A0Q42772433-7008A01B-12C1-4D29-8C6D-7D53371ED3F4Q42772436-6F3586D4-C712-4925-A59A-04BCD8175ECEQ42772440-E2501E1D-28CC-4CF5-841A-0F7A87880C39Q42772441-791B25F7-74B0-47C7-804A-B22FC814CAFBQ42927173-144A5CFA-49EB-472D-B3D0-BF0D687C6BC4Q46069593-A7CF38D1-0AF9-4332-A6E8-D802DB6DC497Q50704853-55BE0508-9E7A-4514-B2B1-6D47A02D4F28Q53577999-7B70240C-0FEB-491D-B96F-FC5DEDEC7211
P2860
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Time to virological failure of ...... from the EuroSIDA study group.
@en
type
label
Time to virological failure of ...... from the EuroSIDA study group.
@en
prefLabel
Time to virological failure of ...... from the EuroSIDA study group.
@en
P2093
P356
P1476
Time to virological failure of ...... from the EuroSIDA study group.
@en
P2093
A N Phillips
A-B E Hansen
B Ledergerber
EuroSIDA Study Group
J D Lundgren
S Staszewski
P304
P356
10.1086/425424
P407
P577
2004-10-28T00:00:00Z